Fate Tx and Carisma Present Clinical Updates in Liquid and Solid Tumors; SITC 2022 Analysis 2
Here is a brief preview of this blast: SITC 2022 Analysis 2: Fate Tx and Carisma presented clinical updates from their novel cell therapies in liquid and solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: